Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04754217 · ClinicalTrials.gov registry record

Valved Graft PMCF Study

A clinical trial of Aortic Valve Disease and Aortic Dissection, sponsored by Abbott Medical Devices.

Recruiting
Registry status
260
Enrollment target
20
Study locations

NCT04754217: Recruiting study of Aortic Valve Disease and Aortic Dissection, sponsored by Abbott Medical Devices.

NCT04754217 is a study of Aortic Valve Disease and Aortic Dissection that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 260 participants, below the 18,600-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04754217, a study of Aortic Valve Disease and Aortic Dissection, is actively recruiting participants, sponsored by Abbott Medical Devices.

RECRUITING
Registry status
260 participants
Enrollment target
20
Study locations

Study Summary

Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.

Primary Outcome

Primary Safety Endpoint

Interventions

  • DEVICE VAVGJ
  • DEVICE CAVGJ

Study Locations (20)

Other

  • Klinik Floridsdorf - Vienna
  • Rigshospitalet - Copenhagen
  • CHU de Besancon - Jean Minjoz - Besançon
  • CHRU Lille - Lille
  • Groupe Hospitalier Bichat - Claude Bernard - Paris
  • Herz-und Diabetes Zentrum NRW - Bad Oeynhausen
  • Deutsches Herzzentrum Berlin - Berlin
  • Klinikum Links der Weser - Bremen
  • Medizinische Hochschule Hannover - Hanover
  • Onassis Cardiac Surgery Center - Athens
  • Policlinico S.Orsola-Malpighi - Bologna
  • Ospedale San Raffaele - Milan
  • Policlinico San Donato - San Donato Milanese
  • Wojewodzki Szpital Zespolony w Kielcach - Kielce
  • Krakowski Szpital Specjalistyczny im. Jana Pawla II - Krakow

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Alabama

  • University Hospital - Univ. of Alabama at Birmingham (UAB) - Birmingham

Michigan

  • University of Michigan - Ann Arbor

North Carolina

  • Mission Health & Hospitals - Asheville

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2021-07-13
Est. Completion 2029-09
Abbott Medical Devices

261 total trials

What NCT04754217 shows while recruiting

NCT04754217 is an observational study that tracks outcomes without assigning an intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 18,600-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Aortic Valve Disease appearing as the primary indexed condition, and to 2 interventions - of which VAVGJ is the first listed.

NCT04754217 names 20 study sites across 5 states, led by Other, Pennsylvania, Alabama.

Frequently Asked Questions

What is clinical trial NCT04754217 about?

NCT04754217 is a clinical study titled "Valved Graft PMCF Study". Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.

What is the current status of trial NCT04754217?

This trial is currently recruiting. The enrollment target is 260 participants. The study started on 2021-07-13. Estimated completion is 2029-09.

What conditions does trial NCT04754217 study?

This clinical trial studies the following conditions: Aortic Valve Disease, Aortic Dissection, Ascending Aorta Abnormality.

What interventions are being tested in trial NCT04754217?

The interventions under investigation include: VAVGJ (DEVICE), CAVGJ (DEVICE).

Who is sponsoring clinical trial NCT04754217?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04754217 being conducted?

This trial has 20 study locations across Alabama, Michigan, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Valve Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04754217's enrollment target sits among peer trials

260 5th of 15 higher than 11 of 15 other Aortic Valve Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aortic Valve Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02283996 · 260 participants · Phase 4

    Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

  • NCT03276793 · 260 participants · NA

    Brain Connectivity in Depression

  • NCT03407469 · 260 participants

    Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

  • NCT03713125 · 260 participants · NA

    Executive Function in Early Childhood

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04754217, the US trial registry maintained by the National Library of Medicine. NCT04754217 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.